Financial News Feed

Stronger Sell Today ADRO ranks #3657 as SELL CANDIDATE #3657 Weaker Sell

Aduro Biotech stock forecast

ADRO stock forecast

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on June 6) BIOFRONTERA AG/ADR (NASDAQ: BFRA ) BIO-TECHNE Corp (NASDAQ: TECH )(announced a deal to buy University of Minnesota startup B-MoGen technology) Blueprint Medicines Corp (NASDAQ: BPMC ) Zynex Inc. (NASDAQ: ZYXI ) Down In The Dumps (Biotech stocks hitting 52-week lows on June 6) Acorda Therapeutics Inc (NASDAQ: ACOR ) Aduro BioTech Inc (NASDAQ: ADRO ) Akebia Therapeutics Inc (NASDAQ: AKBA ) Aptinyx Inc (NASDAQ: APTX ) Axovant Gene Therapies Ltd (NASDAQ: AXGT )(reported six-month follow-up data from the first dose cohort in the Phase 2 trial of AXO-Lenti-PD for the treatment of Parkinson's disease and also issued pipeline update) Bellicum Pharmaceuticals (NASDAQ: BLCM ) Caladrius Biosciences Inc (NASDAQ: CLBS ) Cellectis SA (NASDAQ: CLLS ) Collegium Pharmaceutical Inc (NASDAQ: COLL ) Dynavax Technologies Corporation (NASDAQ: DVAX ) Evolent Health Inc (NYSE: EVH ) Fennec Pharmaceuticals Inc (NASDAQ: FENC ) Harvard Bioscience, Inc. (NASDAQ: HBIO ) Hemispherx BioPharma, Inc (NYSE: HEB ) IMMURON LTD/S ADR (NASDAQ: IMRN ) IMMUTEP LTD/S ADR (NASDAQ: IMMP ) Invivo Therapeutics Holdings Corp (NASDAQ: NVIV ) MOTIF BIO PLC/S ADR (NASDAQ: MTFB ) Navidea Biopharmaceuticals Inc (NYSE: NAVB ) Neuronetics Inc (NASDAQ: STIM ) Puma Biotechnology Inc (NASDAQ: PBYI ) Seres Therapeutics Inc (NASDAQ: …...

Read more

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on June 3) Adverum Biotechnologies Inc (NASDAQ: ADVM ) Array Biopharma Inc (NASDAQ: ARRY ) Ascendis Pharma A/S (NASDAQ: ASND ) Mirati Therapeutics Inc (NASDAQ: MRTX )(reacted to ASCO presentation on a rival drug by Amgen, Inc. (NASDAQ: AMGN )) Misonix, Inc. (NASDAQ: MSON )(received FDA approval for its ultrasonic surgical platform) Trevi Therapeutics Inc (NASDAQ: TRVI ) (analyst began covering the stock after the IPO quiet period expiry ) Down In The Dumps (Biotech stocks hitting 52-week lows on June 3) Arcus Biosciences Inc (NYSE: RCUS ) Abeona Therapeutics Inc (NASDAQ: ABEO ) Aduro BioTech Inc (NASDAQ: ADRO )(reacted to ASCO presentation on its Phase 1b data for ADU-S100) Akers Biosciences Inc (NASDAQ: AKER ) Aldeyra Therapeutics Inc (NASDAQ: ALDX ) BIOLINERX LTD/S ADR (NASDAQ: BLRX ) Celldex Therapeutics, Inc. (NASDAQ: CLDX )(reacted to ASCO presentation on CDX-3379) Cerus Corporation (NASDAQ: CERS ) ContraVir Pharmaceuticals (NASDAQ: CTRV )(began trading on a reverse split-adjusted basis) Cyclerion Therapeutics Inc (NASDAQ: CYCN ) CytRx Corporation (NASDAQ: CYTR ) Dynavax Technologies Corporation (NASDAQ: DVAX ) Evogene Ltd …...

Read more

Biotech stocks came under pressure this week ahead of the ASCO 2019 presentations. Headlines on legal woes related to the opioid crisis and drug price manipulation led to weakness in some stocks. The unfolding week is all about the presentations at one of the largest educational and scientific events for the oncology community. Here are the key events/catalysts to look forward to: Conferences The American Society of Clinical Oncology, or ASCO, 2019 Annual Meeting – May 31–June 4, in Chicago, Illinois The European Academy of Allergy and Clinical Immunology 2019 Annual Congress – June 1-5, in Lisbon, Portugal 20th Global Nephrologists Annual Meeting - June 3-4, in London Jefferies 2019 Healthcare Conference – June 4-7, in New York City European Society for Pediatric Gastroenterology, Hepatology and Nutrition 2019 Annual Meeting – June 5-8, in Glasgow, Scotland HBV Cure Meeting – June 7-8, in Singapore The American Diabetes Association's 79th Scientific Sessions – June 7-11, in San Francisco, California PDUFA Dates The FDA is scheduled to rule Monday on Merck & Co., Inc. (NYSE: MRK )'s sNDA for Zerbaxa (ceftolozone and tazobactam) in treating adult patients with ventilated nosocomial (hospital-acquired) pneumonia ASCO Presentations On Sunday, June 2 Aduro BioTech Inc (NASDAQ: ADRO ) – Phase 1b data for ADU-S100 and Spartalozumab (solid tumors or lymphomas) Celgene Corporation (NASDAQ: CELG ) – Phase 1/2 data on CC-220 (relapsed and/or refractory multiple myeloma) CAN-FITE BIOPHA/S ADR (NYSE: CANF ) – already-released Phase 2 data for Namodenoson (second-line treatment of advanced liver cancer) Amgen, Inc. (NASDAQ: AMGN ) – Phase 1 data for AMG 420 (relapsed, refractory multiple myeloma) ZIOPHARM Oncology Inc. (NASDAQ: ZIOP ) – Phase 1 data for Ad-RTS-Hil-12 (recurrent glioblastoma) as well as initial Phase …...

Read more

Aduro Biotech (ADRO) delivered earnings and revenue surprises of -70.59% and -51.23%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?...

Read more

No summary available....

Read more

The Zacks Analyst Blog Highlights: Incyte, Aduro Biotech, MeiraGTx and Coherus BioSciences...

Read more

Aduro Biotech (ADRO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations....

Read more

Aduro Biotech (ADRO) Signal & Momentum Update
06:50am, Tuesday, 02'nd Apr 2019
Interested investors might be taking a look at the medium range signals for Aduro Biotech (ADRO). The reading from the 40-day commodity channel index is currently Hold. The CCI indicator is mainly use...

Read more

Analysts expect Aduro BioTech, Inc. (NASDAQ:ADRO) to report $-0.22 EPS on May, 1.They anticipate $0.06 EPS change or 21.43 % from last quarter's $-0.28 EPS....

Read more

Traders and investors may be taking note of Aduro Biotech (ADRO) shares and how they are expected to move mid-term. The reading from the 40-day commodity channel index is currently Hold. The CCI indic...

Read more

This is a contrast between Aduro BioTech Inc. (NASDAQ:ADRO) and ArQule Inc. (NASDAQ:ARQL) based on their analyst recommendations, profitability, risk, dividends, earnings and valuation, institutional ...

Read more

As Biotechnology businesses, Aduro BioTech Inc. (NASDAQ:ADRO) and Five Prime Therapeutics Inc. (NASDAQ:FPRX), are affected by compare. This especially applies to their dividends, analyst recommendatio...

Read more

The primary goal for some beginner traders might be just trying to survive. Traders that are disciplined with their money management may be able to better ride out the bumps that come with inexperienc...

Read more

Since Aduro BioTech Inc. (NASDAQ:ADRO) and Aptinyx Inc. (NASDAQ:APTX) are part of the Biotechnology industry, they are influenced by contrast. The influences...

Read more

Proudly made at

Rise Vilnius
in partnership with
Barclays Bank